Mediwound Stock Performance
| MDWD Stock | USD 19.50 0.83 4.08% |
On a scale of 0 to 100, Mediwound holds a performance score of 5. The company secures a Beta (Market Risk) of 0.3, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Mediwound's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mediwound is expected to be smaller as well. Please check Mediwound's information ratio, downside variance, day median price, as well as the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Mediwound's current price movements will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mediwound are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Mediwound exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.08) | Five Day Return (1.32) | Year To Date Return 8.33 | Ten Year Return (65.94) | All Time Return (83.87) |
Last Split Factor 1:7 | Last Split Date 2022-12-20 |
1 | MediWound to Release Earnings on Tuesday - MarketBeat | 11/18/2024 |
2 | What To Expect From MediWound Ltd Q3 2024 Earnings | 11/25/2024 |
3 | MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update | 11/26/2024 |
4 | MediWound Ltd Q3 2024 Earnings Call Highlights Strategic Advances Amid Financial Challenges | 11/27/2024 |
5 | Earnings Update MediWound Ltd. Just Reported And Analysts Are Trimming Their Forecasts | 11/29/2024 |
6 | MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2... | 12/17/2024 |
7 | Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 | 01/08/2025 |
8 | MediWound Surges 8.5 percent Is This an Indication of Further Gains | 01/27/2025 |
9 | MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference | 02/04/2025 |
| Begin Period Cash Flow | 33.9 M |
Mediwound |
Mediwound Relative Risk vs. Return Landscape
If you would invest 1,739 in Mediwound on November 9, 2024 and sell it today you would earn a total of 211.00 from holding Mediwound or generate 12.13% return on investment over 90 days. Mediwound is currently generating 0.2467% in daily expected returns and assumes 3.2862% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Mediwound, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mediwound Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mediwound's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mediwound, and traders can use it to determine the average amount a Mediwound's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0751
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MDWD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.29 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 5 95% of assets perform better |
Based on monthly moving average Mediwound is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mediwound by adding it to a well-diversified portfolio.
Mediwound Fundamentals Growth
Mediwound Stock prices reflect investors' perceptions of the future prospects and financial health of Mediwound, and Mediwound fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mediwound Stock performance.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 171.3 M | ||||
| Shares Outstanding | 10.79 M | ||||
| Price To Earning | 16.58 X | ||||
| Price To Book | 6.15 X | ||||
| Price To Sales | 10.45 X | ||||
| Revenue | 18.69 M | ||||
| Gross Profit | 2.67 M | ||||
| EBITDA | (4.89 M) | ||||
| Net Income | (6.72 M) | ||||
| Cash And Equivalents | 10.41 M | ||||
| Cash Per Share | 0.31 X | ||||
| Total Debt | 6.35 M | ||||
| Debt To Equity | 0.64 % | ||||
| Current Ratio | 1.61 X | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | (10.46 M) | ||||
| Earnings Per Share | (2.91) X | ||||
| Market Capitalization | 210.4 M | ||||
| Total Asset | 66.46 M | ||||
| Retained Earnings | (174.82 M) | ||||
| Working Capital | 38.87 M | ||||
| Current Asset | 50.4 M | ||||
| Current Liabilities | 5.21 M | ||||
About Mediwound Performance
By analyzing Mediwound's fundamental ratios, stakeholders can gain valuable insights into Mediwound's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mediwound has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mediwound has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 79.07 | 75.12 | |
| Return On Tangible Assets | (0.10) | (0.12) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.10) | (0.12) | |
| Return On Equity | (0.24) | (0.26) |
Things to note about Mediwound performance evaluation
Checking the ongoing alerts about Mediwound for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mediwound help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mediwound had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 18.69 M. Net Loss for the year was (6.72 M) with profit before overhead, payroll, taxes, and interest of 2.67 M. | |
| Mediwound currently holds about 10.41 M in cash with (10.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
- Analyzing Mediwound's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mediwound's stock is overvalued or undervalued compared to its peers.
- Examining Mediwound's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mediwound's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mediwound's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mediwound's stock. These opinions can provide insight into Mediwound's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |